<DOC>
	<DOCNO>NCT00604812</DOCNO>
	<brief_summary>A study ass safety , tolerability , single dose pharmacokinetics market drug pediatric subject migraine . After completion portion study ( Panels A B ) , regulatory agency issue amend request 12-17 year old age group study include similar number male female subject . Therefore , study amend add additional panel subject ( Panel C ) ensure gender balance specifically age group .</brief_summary>
	<brief_title>Drug Study Pediatric Subjects With Migraines ( MK0462-083 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Rizatriptan</mesh_term>
	<criteria>Panel A B : Male female subject ( nonsmoker ) age 6 17 history migraine Panel C : Male subject ( nonsmoker ) age 12 17 history migraine Subject history migraine headache , experience migraine day study drug administration Subject history migraine headache Taking medication monoamine oxidase inhibitor ( MAOI ) selective serotonin reuptake inhibitor ( SSRI ) Subject condition , opinion investigator , may interfere optimal participation study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>